New CAR t combo takes on Hard-to-Treat myeloma

NCT ID NCT07221032

Not yet recruiting Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This early-phase trial tests a new type of CAR T-cell therapy called FT836, given together with the drug daratumumab, in 12 adults with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if the combination is safe and to find the best dose. Participants receive FT836 cells by IV and daratumumab by IV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FT836 CAR T-cells and daratumumab (Darzalex)
What this could lead to: If it works, this could point toward a new combination treatment for multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is a very early, small phase 1 trial with only 12 participants. It is designed mainly to check safety and find the right dose, not to prove effectiveness. Side effects like cytokine release syndrome are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY MULTIPLE MYELOMA RELAPSE MULTIPLE MYELOMA

Contacts and locations

Locations

Froedtert & the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.